|

Impact of Gonadotoxic Therapies on Fertility

RECRUITINGSponsored by Michael von Wolff
Actively Recruiting
SponsorMichael von Wolff
Started2023-12-01
Est. completion2028-12-31
Eligibility
Age14 Years – 50 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05885048

Summary

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer. The main questions it aims to answer are: * in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve); * in males, if cancer therapies reduce sperm concentration (sperm quality).

Eligibility

Age: 14 Years – 50 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with cancer or with benign reasons undergoing chemotherapy and/or radiotherapy of the pelvis (females) and the testicles (males) and/or immune therapy;
* Willing to participate;
* Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults);
* Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males).

Exclusion Criteria:

* Missing consent;
* Language barrier.

Conditions6

CancerEffects of ImmunotherapyFertility IssuesFertility PreservationToxicity Due to ChemotherapyToxicity Due to Radiotherapy

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.